Legal Representation
Attorney
Neil C. Jones
USPTO Deadlines
Next Deadline
3 days remaining
Published for Opposition
Due Date
January 08, 2026
Extension Available
Until February 08, 2026
Application History
21 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Dec 9, 2025 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Dec 9, 2025 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Dec 3, 2025 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| Nov 13, 2025 | CNSA | O | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Nov 10, 2025 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Nov 10, 2025 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Nov 10, 2025 | ERFR | I | TEAS REQUEST FOR RECONSIDERATION RECEIVED | Loading... |
| Aug 29, 2025 | GNFN | O | NOTIFICATION OF FINAL REFUSAL EMAILED | Loading... |
| Aug 29, 2025 | GNFR | O | FINAL REFUSAL E-MAILED | Loading... |
| Aug 29, 2025 | CNFR | R | FINAL REFUSAL WRITTEN | Loading... |
| Aug 6, 2025 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Aug 6, 2025 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Aug 6, 2025 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| May 6, 2025 | XELG | O | APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED | Loading... |
| May 6, 2025 | XELR | I | APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED | Loading... |
| Feb 6, 2025 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| Feb 6, 2025 | GNRT | F | NON-FINAL ACTION E-MAILED | Loading... |
| Feb 6, 2025 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Feb 6, 2025 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Jan 23, 2025 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Jul 30, 2024 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 005
Full line of pharmaceutical products, namely pharmaceutical products and preparations for treating diseases and conditions in gynecology and women's health, pharmaceutical products and preparations for use as prenatal supplements, pharmaceutical products and preparations for use as iron supplements, pharmaceutical products and preparations for use as multivitamin and mineral supplements, vitamin supplements and nutraceuticals for use as dietary supplements, pharmaceutical products and preparations for treating symptoms associated with menopause, pharmaceutical products and preparations for treating menopause and post menopause symptoms and conditions, pharmaceutical products and preparations for use in pain management, pharmaceutical products and preparations for use as opioid analgesics, pharmaceutical products and preparations for treating musculoskeletal conditions, and pharmaceutical products and preparations for use as a centrally-acting agents for musculoskeletal conditions; pharmaceutical preparations for managing and relieving pain and inflammation, pharmaceutical preparations for use in the treatment of musculoskeletal conditions, soft tissue conditions, and arthritis, pharmaceutical preparations for the treatment of diseases and disorders of the central nervous system, namely, attention deficit disorder, attention deficit hyperactivity disorder, hyperactivity, and executive functioning disorder, and pharmaceutical products and preparations for use as antidepressants
First Use Anywhere:
Oct 25, 2013
First Use in Commerce:
Oct 25, 2013
Class 042
Pharmaceutical products development; Development of pharmaceutical preparations and medicines; Pharmaceutical research and development; Pharmaceutical company services, namely, professional medical company services being pharmaceutical product research and development; Generic pharmaceutical research and development
First Use Anywhere:
Oct 25, 2013
First Use in Commerce:
Oct 25, 2013
Additional Information
Pseudo Mark
TRI GEN
Classification
International Classes
005
042